222 related articles for article (PubMed ID: 25792115)
1. Antibacterial activity of fosfomycin against uropathogens.
Sun F; Chen S; Qiu X; Sun Y; Feng W; Chen J; Xia P
Chemotherapy; 2014; 60(3):157-61. PubMed ID: 25792115
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
Araj GF; Jaber FA
J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
[TBL] [Abstract][Full Text] [Related]
5. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
6. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options.
Origüen J; Fernández-Ruiz M; López-Medrano F; Ruiz-Merlo T; González E; Morales JM; Fiorante S; San-Juan R; Villa J; Orellana MÁ; Andrés A; Aguado JM
Transpl Infect Dis; 2016 Aug; 18(4):575-84. PubMed ID: 27373698
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
[TBL] [Abstract][Full Text] [Related]
8. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
[TBL] [Abstract][Full Text] [Related]
9. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
Hernández MS; García JA; Muñoz JL
Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China.
Jiang Y; Shen P; Wei Z; Liu L; He F; Shi K; Wang Y; Wang H; Yu Y
Int J Antimicrob Agents; 2015 Jan; 45(1):66-70. PubMed ID: 25450805
[TBL] [Abstract][Full Text] [Related]
12. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3.
Lee SY; Park YJ; Yu JK; Jung S; Kim Y; Jeong SH; Arakawa Y
J Antimicrob Chemother; 2012 Dec; 67(12):2843-7. PubMed ID: 22893681
[TBL] [Abstract][Full Text] [Related]
14. Incidence of multidrug resistance and extended-spectrum beta-lactamase expression in community-acquired urinary tract infection among different age groups of patients.
Fatima S; Muhammad IN; Usman S; Jamil S; Khan MN; Khan SI
Indian J Pharmacol; 2018; 50(2):69-74. PubMed ID: 30100654
[TBL] [Abstract][Full Text] [Related]
15. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia.
Kader AA; Angamuthu K
Saudi Med J; 2005 Jun; 26(6):956-9. PubMed ID: 15983682
[TBL] [Abstract][Full Text] [Related]
16. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
Garau J
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
[TBL] [Abstract][Full Text] [Related]
17. CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia.
Martinez P; Garzón D; Mattar S
Braz J Infect Dis; 2012; 16(5):420-5. PubMed ID: 22964287
[TBL] [Abstract][Full Text] [Related]
18. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy.
Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Mouton JW; Peleg AY
J Microbiol Methods; 2020 Apr; 171():105861. PubMed ID: 32035114
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
Demir T; Buyukguclu T
Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
